Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine

Xiaohong Sun, Xiyu Wang, Guo Du Wang, Yun Xia, Sumei Liu, Meihua Qu, Bradley J. Needleman, Dean J. Mikami, W. Scott Melvin, Laura M. Bohn, Ryuji Ueno, Jackie D. Wood

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background and Aims: Treatments with morphine or opioid agonists cause constipation. Lubiprostone is approved for treatment of adult idiopathic constipation and constipation-predominant IBS in adult women. We tested whether lubiprostone can reverse morphine-suppression of mucosal secretion in human intestine and explored the mechanism of action. Methods: Fresh segments of jejunum discarded during Roux-En-Y gastric bypass surgeries were used. Changes in short-circuit current (ΔIsc) were recorded in Ussing flux chambers as a marker for electrogenic chloride secretion during pharmacological interactions between morphine, prostaglandin receptor antagonists, chloride channel blockers and lubiprostone. Results: Morphine suppressed basal Isc. Lubiprostone reversed morphine suppression of basal Isc. Lubiprostone, applied to the mucosa in concentrations ranging from 3 nM to 30 μM, evoked increases in Isc in concentration-dependent manner when applied to the mucosal side of muscle-stripped preparations. Blockade of enteric nerves did not change stimulation of Isc by lubiprostone. Removal of chloride or application of bumetanide or NPPB suppressed or abolished responses to lubiprostone. Antagonists acting at CFTR channels and prostaglandin EP4 receptors, but not at E1, EP1-3 receptors, partially suppressed stimulation of Isc by lubiprostone. Conclusions: Antisecretory action of morphine results from suppression of excitability of secretomotor neurons in the enteric nervous system. Lubiprostone, which does not affect enteric neurons directly, bypasses the action of morphine by directly opening mucosal chloride channels.

Original languageEnglish (US)
Pages (from-to)330-338
Number of pages9
JournalDigestive Diseases and Sciences
Volume56
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Morphine
Small Intestine
Constipation
Chloride Channels
Chlorides
Receptors, Prostaglandin E, EP4 Subtype
Prostaglandin Receptors
Enteric Nervous System
Bumetanide
Lubiprostone
Neurons
Prostaglandin Antagonists
Gastric Bypass
Nerve Block
mu Opioid Receptor
Jejunum
Opioid Analgesics
Intestines
Mucous Membrane
Pharmacology

Keywords

  • CFTR
  • ClC-2 channels
  • Constipation
  • Enteric nervous system
  • Irritable bowel syndrome
  • Mucosal secretion
  • Opioid analgesics
  • Prostaglandins

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. / Sun, Xiaohong; Wang, Xiyu; Wang, Guo Du; Xia, Yun; Liu, Sumei; Qu, Meihua; Needleman, Bradley J.; Mikami, Dean J.; Melvin, W. Scott; Bohn, Laura M.; Ueno, Ryuji; Wood, Jackie D.

In: Digestive Diseases and Sciences, Vol. 56, No. 2, 02.2011, p. 330-338.

Research output: Contribution to journalArticle

Sun, X, Wang, X, Wang, GD, Xia, Y, Liu, S, Qu, M, Needleman, BJ, Mikami, DJ, Melvin, WS, Bohn, LM, Ueno, R & Wood, JD 2011, 'Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine', Digestive Diseases and Sciences, vol. 56, no. 2, pp. 330-338. https://doi.org/10.1007/s10620-010-1515-8
Sun, Xiaohong ; Wang, Xiyu ; Wang, Guo Du ; Xia, Yun ; Liu, Sumei ; Qu, Meihua ; Needleman, Bradley J. ; Mikami, Dean J. ; Melvin, W. Scott ; Bohn, Laura M. ; Ueno, Ryuji ; Wood, Jackie D. / Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. In: Digestive Diseases and Sciences. 2011 ; Vol. 56, No. 2. pp. 330-338.
@article{0ade583c97724e33b7581958e3f7fd44,
title = "Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine",
abstract = "Background and Aims: Treatments with morphine or opioid agonists cause constipation. Lubiprostone is approved for treatment of adult idiopathic constipation and constipation-predominant IBS in adult women. We tested whether lubiprostone can reverse morphine-suppression of mucosal secretion in human intestine and explored the mechanism of action. Methods: Fresh segments of jejunum discarded during Roux-En-Y gastric bypass surgeries were used. Changes in short-circuit current (ΔIsc) were recorded in Ussing flux chambers as a marker for electrogenic chloride secretion during pharmacological interactions between morphine, prostaglandin receptor antagonists, chloride channel blockers and lubiprostone. Results: Morphine suppressed basal Isc. Lubiprostone reversed morphine suppression of basal Isc. Lubiprostone, applied to the mucosa in concentrations ranging from 3 nM to 30 μM, evoked increases in Isc in concentration-dependent manner when applied to the mucosal side of muscle-stripped preparations. Blockade of enteric nerves did not change stimulation of Isc by lubiprostone. Removal of chloride or application of bumetanide or NPPB suppressed or abolished responses to lubiprostone. Antagonists acting at CFTR channels and prostaglandin EP4 receptors, but not at E1, EP1-3 receptors, partially suppressed stimulation of Isc by lubiprostone. Conclusions: Antisecretory action of morphine results from suppression of excitability of secretomotor neurons in the enteric nervous system. Lubiprostone, which does not affect enteric neurons directly, bypasses the action of morphine by directly opening mucosal chloride channels.",
keywords = "CFTR, ClC-2 channels, Constipation, Enteric nervous system, Irritable bowel syndrome, Mucosal secretion, Opioid analgesics, Prostaglandins",
author = "Xiaohong Sun and Xiyu Wang and Wang, {Guo Du} and Yun Xia and Sumei Liu and Meihua Qu and Needleman, {Bradley J.} and Mikami, {Dean J.} and Melvin, {W. Scott} and Bohn, {Laura M.} and Ryuji Ueno and Wood, {Jackie D.}",
year = "2011",
month = "2",
doi = "10.1007/s10620-010-1515-8",
language = "English (US)",
volume = "56",
pages = "330--338",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "2",

}

TY - JOUR

T1 - Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine

AU - Sun, Xiaohong

AU - Wang, Xiyu

AU - Wang, Guo Du

AU - Xia, Yun

AU - Liu, Sumei

AU - Qu, Meihua

AU - Needleman, Bradley J.

AU - Mikami, Dean J.

AU - Melvin, W. Scott

AU - Bohn, Laura M.

AU - Ueno, Ryuji

AU - Wood, Jackie D.

PY - 2011/2

Y1 - 2011/2

N2 - Background and Aims: Treatments with morphine or opioid agonists cause constipation. Lubiprostone is approved for treatment of adult idiopathic constipation and constipation-predominant IBS in adult women. We tested whether lubiprostone can reverse morphine-suppression of mucosal secretion in human intestine and explored the mechanism of action. Methods: Fresh segments of jejunum discarded during Roux-En-Y gastric bypass surgeries were used. Changes in short-circuit current (ΔIsc) were recorded in Ussing flux chambers as a marker for electrogenic chloride secretion during pharmacological interactions between morphine, prostaglandin receptor antagonists, chloride channel blockers and lubiprostone. Results: Morphine suppressed basal Isc. Lubiprostone reversed morphine suppression of basal Isc. Lubiprostone, applied to the mucosa in concentrations ranging from 3 nM to 30 μM, evoked increases in Isc in concentration-dependent manner when applied to the mucosal side of muscle-stripped preparations. Blockade of enteric nerves did not change stimulation of Isc by lubiprostone. Removal of chloride or application of bumetanide or NPPB suppressed or abolished responses to lubiprostone. Antagonists acting at CFTR channels and prostaglandin EP4 receptors, but not at E1, EP1-3 receptors, partially suppressed stimulation of Isc by lubiprostone. Conclusions: Antisecretory action of morphine results from suppression of excitability of secretomotor neurons in the enteric nervous system. Lubiprostone, which does not affect enteric neurons directly, bypasses the action of morphine by directly opening mucosal chloride channels.

AB - Background and Aims: Treatments with morphine or opioid agonists cause constipation. Lubiprostone is approved for treatment of adult idiopathic constipation and constipation-predominant IBS in adult women. We tested whether lubiprostone can reverse morphine-suppression of mucosal secretion in human intestine and explored the mechanism of action. Methods: Fresh segments of jejunum discarded during Roux-En-Y gastric bypass surgeries were used. Changes in short-circuit current (ΔIsc) were recorded in Ussing flux chambers as a marker for electrogenic chloride secretion during pharmacological interactions between morphine, prostaglandin receptor antagonists, chloride channel blockers and lubiprostone. Results: Morphine suppressed basal Isc. Lubiprostone reversed morphine suppression of basal Isc. Lubiprostone, applied to the mucosa in concentrations ranging from 3 nM to 30 μM, evoked increases in Isc in concentration-dependent manner when applied to the mucosal side of muscle-stripped preparations. Blockade of enteric nerves did not change stimulation of Isc by lubiprostone. Removal of chloride or application of bumetanide or NPPB suppressed or abolished responses to lubiprostone. Antagonists acting at CFTR channels and prostaglandin EP4 receptors, but not at E1, EP1-3 receptors, partially suppressed stimulation of Isc by lubiprostone. Conclusions: Antisecretory action of morphine results from suppression of excitability of secretomotor neurons in the enteric nervous system. Lubiprostone, which does not affect enteric neurons directly, bypasses the action of morphine by directly opening mucosal chloride channels.

KW - CFTR

KW - ClC-2 channels

KW - Constipation

KW - Enteric nervous system

KW - Irritable bowel syndrome

KW - Mucosal secretion

KW - Opioid analgesics

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=79952440832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952440832&partnerID=8YFLogxK

U2 - 10.1007/s10620-010-1515-8

DO - 10.1007/s10620-010-1515-8

M3 - Article

VL - 56

SP - 330

EP - 338

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 2

ER -